WE SELL NOTHING✳EVERY CLAIM → A PRIMARY SOURCE✳UNKNOWN IS A REAL ANSWER✳NO PRODUCTS · NO PROTOCOLS · NO VENDORS✳WE SELL NOTHING✳EVERY CLAIM → A PRIMARY SOURCE✳UNKNOWN IS A REAL ANSWER✳
← All Claim Checks
Source record · FDA approval record · reviewed July 17, 2026

Forzinity has a real approval. Anti-aging and general-energy claims are outside it.

Misleading
The circulating claim

“Elamipretide is FDA-approved for anti-aging, energy, and mitochondrial health.”

What the source record says

FDA granted accelerated approval to Forzinity for improving muscle strength in people with Barth syndrome who weigh at least 30 kg. The pivotal record involved 12 patients with that rare disease and does not establish anti-aging or general wellness benefits.

Why the claim misleads

A narrow rare-disease product approval is being widened to new populations, outcomes, and products.

Correction

Forzinity has a real approval. Anti-aging and general-energy claims are outside it.

Primary sources
FDA accelerated-approval announcementOpen source ↗FDA Drug Trials Snapshot: ForzinityOpen source ↗Elamipretide / Forzinity library entryOpen source ↗
What changed

Added the 2025 accelerated approval and clarified the exact product, population, endpoint basis, and limits of that approval.

What would change our answer

Label changes, confirmatory-trial results, or a new FDA action could change the approved scope or confidence. Evidence in people without Barth syndrome would need separate review.

Version history · 1 entry
  1. v1 · 2026-07-17Initial source-verified approval, evidence, and limitation record.Source ↗
Boundary: This check evaluates a public claim. It does not assess an individual product or person and is not treatment, dosing, sourcing, or legal advice.